Machine learning

The company will use the investment to deploy its technology in more healthcare facilities.

The multinational pharma company will now be able to access Tempus' de-identified patient data.

The company will use the funds to expand its platform and accelerate global commercialization.

The startup builds machine learning tools that aim to understand speech, feelings and nonverbal cues like sighs, laughs and gasps.

A review published in JAMA Network Open evaluated 41 RCTs of machine learning interventions. None of the studies fully followed CONSORT-AI standards, a set of guidelines developed for clinical trials evaluating medical interventions that include AI.

Mati Gil, CEO of AION Labs, describes how its new startup OMEC.AI came to fruition and what it aims to accomplish for drug discovery and development. 

The startup's tool records and transcribes conversations between providers and patients, and then organizes relevant information about health conditions, symptoms and next steps.

The device allows them to use handheld controllers to play video games.

This collaboration will work with an unnamed pharma company in Japan to know how its drugs behave compared to rival products.

The proposed system uses brain signals and neural patterns from children.